## Fluoroquinolones in Respiratory Tract Infections **Key Point:** Moxifloxacin is the preferred fluoroquinolone for acute exacerbation of chronic bronchitis (AECB) and community-acquired pneumonia (CAP) due to superior respiratory coverage. ### Why Moxifloxacin? Moxifloxacin is a **fourth-generation (respiratory) fluoroquinolone** with enhanced activity against: - Streptococcus pneumoniae (including penicillin-resistant strains) - Haemophilus influenzae - Moraxella catarrhalis - Atypical pathogens (Mycoplasma, Chlamydia, Legionella) - Anaerobes (unique among fluoroquinolones) **High-Yield:** Moxifloxacin has the broadest spectrum among fluoroquinolones and is specifically indicated for respiratory infections in guidelines. ### Comparison with Other Fluoroquinolones | Feature | Moxifloxacin | Levofloxacin | Ofloxacin | Ciprofloxacin | |---------|--------------|--------------|-----------|---------------| | **Generation** | 4th | 3rd | 2nd | 2nd | | **S. pneumoniae coverage** | Excellent | Good | Poor | Poor | | **Anaerobe coverage** | Yes | No | No | No | | **Respiratory use** | First-line | Alternative | Not preferred | Not preferred | | **Gram-negative coverage** | Good | Good | Good | Excellent | **Clinical Pearl:** Levofloxacin is a reasonable alternative for AECB if moxifloxacin is contraindicated, but moxifloxacin remains superior due to anaerobic and atypical coverage. ### Mechanism of Superiority Moxifloxacin's enhanced gram-positive and anaerobic activity stems from: 1. Methyl group at position 8 (increased potency) 2. Fluorine at position 6 (improved bacterial penetration) 3. Better lung tissue penetration and bioavailability **Mnemonic:** **MOXI** for **Respiratory** = **M**ethyl group makes it **M**ost suitable for **M**ajor respiratory infections.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.